Possibilities of immunoprophylaxis and immunotherapy in gut-derived infectious-toxic shock (GITS).
Imbach
P
P
Central Laboratory, Swiss Red Cross Blood Transfusion Service, Bern.
Hässig
A
A
Cottier
H
H
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000907:Antibodies, Bacterial / Q000276:immunology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D004731:Endotoxins / Q000009:adverse effects / Q000276:immunology; D006090:Gram-Negative Bacteria / Q000276:immunology; D016905:Gram-Negative Bacterial Infections / Q000276:immunology / Q000628:therapy; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use; D007167:Immunotherapy; D007422:Intestines / Q000382:microbiology*; D008070:Lipopolysaccharides / Q000276:immunology; D012772:Shock, Septic / Q000517:prevention & control / Q000628:therapy*
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D004731:Endotoxins; D016756:Immunoglobulins, Intravenous; D008070:Lipopolysaccharides